Overview

Effect of GSK1160724 In Healthy Volunteers

Status:
Completed
Trial end date:
2008-04-07
Target enrollment:
Participant gender:
Summary
GSK1160724 is a potent mAChR antagonist, which is being developed for treatment of chronic obstructive pulmonary disease (COPD)
Phase:
Phase 1
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Bromides
Tiotropium Bromide